You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOmacetaxine mepesuccinate
Accession NumberDB04865
TypeSmall Molecule
GroupsApproved
DescriptionOmacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Structure
Thumb
Synonyms
(−)-homoharringtonine
(2'R,3S,4S,5R)-(−)-homoharringtonine
HHT
Homoharringtonin
Homoharringtonine
External Identifiers
  • CGX-635
  • NSC-141633
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Synriboinjection, powder, lyophilized, for solution3.5 mg/mLsubcutaneousCephalon, Inc.2012-11-19Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CeflatoninChemGenex Therapeutics
MyelostatNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Omacetaxine mepesuccinate hydrochloride
457895-79-3
Thumb
  • InChI Key: RRNSZQVHVKGKOS-CALFFDBBSA-N
  • Monoisotopic Mass: 581.2391596
  • Average Mass: 582.09
DBSALT001930
Categories
UNII6FG8041S5B
CAS number26833-87-4
WeightAverage: 545.6213
Monoisotopic: 545.262481851
Chemical FormulaC29H39NO9
InChI KeyHYFHYPWGAURHIV-JFIAXGOJSA-N
InChI
InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1
IUPAC Name
(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.0²,⁶.0⁶,¹⁰.0¹⁵,¹⁹]icosa-1(20),4,13,15(19)-tetraen-3-yl 1-methyl (3R)-3-hydroxy-3-(4-hydroxy-4-methylpentyl)butanedioate
SMILES
[H][C@@]1(OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@]23CCCN2CCC2=CC4=C(OCO4)C=C2[C@]13[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cephalotaxus alkaloids. These are alkaloids with a structure based on the cephalotaxine skeleton, a tetracyclic 1,3-benzodioxole-containing compound which arises from the skeletal rearrangement of the hydroaromatic component of the Erythrina group.
KingdomOrganic compounds
Super ClassAlkaloids and derivatives
ClassCephalotaxus alkaloids
Sub ClassNot Available
Direct ParentCephalotaxus alkaloids
Alternative Parents
Substituents
  • Cephalotaxine
  • Cephalotaxus alkaloid skeleton
  • Benzazepine
  • Benzodioxole
  • Aralkylamine
  • Fatty acid methyl ester
  • Fatty acid ester
  • Beta-hydroxy acid
  • Azepine
  • Fatty acyl
  • Benzenoid
  • N-alkylpyrrolidine
  • Hydroxy acid
  • Dicarboxylic acid or derivatives
  • Methyl ester
  • Tertiary alcohol
  • Pyrrolidine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxylic acid ester
  • Oxacycle
  • Azacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed in patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
PharmacodynamicsThe pharmacodynamics of homoharringtonine is not fully understood. It is known that homoharringtonine is involved with protein synthesis inhibition and this leads to its antineoplastic activity.
Mechanism of actionHomoharringtonine inhibits protein synthesis by not directly binding to Bcr-Abl. It binds to the A-site cleft in the large ribosomal subunit, which affects chain elongation and prevents protein synthesis.
Related Articles
AbsorptionHomoharringtonine absorption was not quantified, but maximum concentration is reached after about 30 mins.
Volume of distribution

Homoharringtonine has a steady state Vd of 141 ± 93.4 L.

Protein bindingPlasma protein binding is equal or less than 50%.
Metabolism

Homoharringtonine has undergoes little hepatic metabolism and is mostly metabolized to 4’-DMHHT by plasma esterase hydrolysis.

Route of eliminationThe main route of elimination for homoharringtonine is still unknown, but renal elimination is less than 15%.
Half lifeHomoharringtonine has a half life of about 6 hours after subcutaneous administration.
Clearance

Clearance for homoharringtonine was not quantified.

ToxicityThe most severe adverse effects after homoharringtonine administration are myelosuppression, bleeding, hyperglycemia, and fetal harm.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8077
Blood Brain Barrier-0.5157
Caco-2 permeable-0.5102
P-glycoprotein substrateSubstrate0.9056
P-glycoprotein inhibitor IInhibitor0.5183
P-glycoprotein inhibitor IINon-inhibitor0.8527
Renal organic cation transporterNon-inhibitor0.7406
CYP450 2C9 substrateNon-substrate0.8857
CYP450 2D6 substrateNon-substrate0.7052
CYP450 3A4 substrateSubstrate0.7613
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9428
Ames testNon AMES toxic0.5243
CarcinogenicityNon-carcinogens0.909
BiodegradationNot ready biodegradable0.993
Rat acute toxicity3.1592 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9292
hERG inhibition (predictor II)Non-inhibitor0.8032
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionsubcutaneous3.5 mg/mL
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6987103 No2003-06-282023-06-28Us
USRE45128 No1999-03-162019-03-16Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.108 mg/mLALOGPS
logP2.09ALOGPS
logP1.88ChemAxon
logS-3.7ALOGPS
pKa (Strongest Acidic)12.09ChemAxon
pKa (Strongest Basic)9.42ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area123.99 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity142.07 m3·mol-1ChemAxon
Polarizability57.62 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Yaguang Liu, “Process for producing harringtonine and homoharringtonine.” U.S. Patent US4783454, issued June, 1980.

US4783454
General References
  1. Lou YJ, Qian WB, Jin J: Homoharringtonine induces apoptosis and growth arrest in human myeloma cells. Leuk Lymphoma. 2007 Jul;48(7):1400-6. [PubMed:17613769 ]
  2. Jie H, Donghua H, Xingkui X, Liang G, Wenjun W, Xiaoyan H, Zhen C: Homoharringtonine-induced apoptosis of MDS cell line MUTZ-1 cells is mediated by the endoplasmic reticulum stress pathway. Leuk Lymphoma. 2007 May;48(5):964-77. [PubMed:17487741 ]
External Links
ATC CodesL01XX40
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (170 KB)
MSDSDownload (68.5 KB)
Interactions
Drug Interactions
Drug
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Omacetaxine mepesuccinate.
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Omacetaxine mepesuccinate.
AcenocoumarolThe risk or severity of adverse effects can be increased when Acenocoumarol is combined with Omacetaxine mepesuccinate.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Omacetaxine mepesuccinate.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Omacetaxine mepesuccinate.
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Omacetaxine mepesuccinate.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Omacetaxine mepesuccinate.
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Omacetaxine mepesuccinate.
ApixabanThe risk or severity of adverse effects can be increased when Apixaban is combined with Omacetaxine mepesuccinate.
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Omacetaxine mepesuccinate.
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Omacetaxine mepesuccinate.
ArgatrobanThe risk or severity of adverse effects can be increased when Argatroban is combined with Omacetaxine mepesuccinate.
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Omacetaxine mepesuccinate.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Omacetaxine mepesuccinate.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Omacetaxine mepesuccinate.
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Omacetaxine mepesuccinate.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Omacetaxine mepesuccinate.
BevacizumabBevacizumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Omacetaxine mepesuccinate.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Omacetaxine mepesuccinate.
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Omacetaxine mepesuccinate.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Omacetaxine mepesuccinate.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Omacetaxine mepesuccinate.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Omacetaxine mepesuccinate.
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Omacetaxine mepesuccinate.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Omacetaxine mepesuccinate.
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Omacetaxine mepesuccinate.
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Omacetaxine mepesuccinate.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Omacetaxine mepesuccinate.
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Omacetaxine mepesuccinate.
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Omacetaxine mepesuccinate.
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Omacetaxine mepesuccinate.
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Omacetaxine mepesuccinate.
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Omacetaxine mepesuccinate.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Omacetaxine mepesuccinate.
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Omacetaxine mepesuccinate.
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Omacetaxine mepesuccinate.
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Omacetaxine mepesuccinate.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Omacetaxine mepesuccinate.
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Omacetaxine mepesuccinate.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Omacetaxine mepesuccinate.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
DigoxinDigoxin may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Omacetaxine mepesuccinate.
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Omacetaxine mepesuccinate.
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Omacetaxine mepesuccinate.
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Omacetaxine mepesuccinate.
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Omacetaxine mepesuccinate.
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Omacetaxine mepesuccinate.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Omacetaxine mepesuccinate.
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Omacetaxine mepesuccinate.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Omacetaxine mepesuccinate.
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Omacetaxine mepesuccinate.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Omacetaxine mepesuccinate.
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Omacetaxine mepesuccinate.
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Omacetaxine mepesuccinate.
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Omacetaxine mepesuccinate.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Omacetaxine mepesuccinate.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Omacetaxine mepesuccinate.
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Omacetaxine mepesuccinate.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Omacetaxine mepesuccinate.
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Omacetaxine mepesuccinate.
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Omacetaxine mepesuccinate.
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Omacetaxine mepesuccinate.
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Omacetaxine mepesuccinate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Omacetaxine mepesuccinate.
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Omacetaxine mepesuccinate.
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Omacetaxine mepesuccinate.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Omacetaxine mepesuccinate.
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Omacetaxine mepesuccinate.
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Omacetaxine mepesuccinate.
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Omacetaxine mepesuccinate.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Omacetaxine mepesuccinate.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Omacetaxine mepesuccinate.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Omacetaxine mepesuccinate.
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Omacetaxine mepesuccinate.
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Omacetaxine mepesuccinate.
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Omacetaxine mepesuccinate.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Omacetaxine mepesuccinate.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Omacetaxine mepesuccinate.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Omacetaxine mepesuccinate.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Omacetaxine mepesuccinate.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Omacetaxine mepesuccinate.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Omacetaxine mepesuccinate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Omacetaxine mepesuccinate.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Omacetaxine mepesuccinate.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Omacetaxine mepesuccinate.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Omacetaxine mepesuccinate.
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Omacetaxine mepesuccinate.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Omacetaxine mepesuccinate.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Omacetaxine mepesuccinate.
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Omacetaxine mepesuccinate.
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Omacetaxine mepesuccinate.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Omacetaxine mepesuccinate.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Omacetaxine mepesuccinate.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Omacetaxine mepesuccinate.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Omacetaxine mepesuccinate.
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Omacetaxine mepesuccinate.
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Omacetaxine mepesuccinate.
OuabainOuabain may decrease the cardiotoxic activities of Omacetaxine mepesuccinate.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Omacetaxine mepesuccinate.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Omacetaxine mepesuccinate.
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Omacetaxine mepesuccinate.
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Omacetaxine mepesuccinate.
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Omacetaxine mepesuccinate.
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Omacetaxine mepesuccinate.
PhenprocoumonThe risk or severity of adverse effects can be increased when Phenprocoumon is combined with Omacetaxine mepesuccinate.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Omacetaxine mepesuccinate.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Omacetaxine mepesuccinate.
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Omacetaxine mepesuccinate.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Omacetaxine mepesuccinate.
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Omacetaxine mepesuccinate.
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Omacetaxine mepesuccinate.
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Omacetaxine mepesuccinate.
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Omacetaxine mepesuccinate.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Omacetaxine mepesuccinate.
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Omacetaxine mepesuccinate.
RivaroxabanThe risk or severity of adverse effects can be increased when Rivaroxaban is combined with Omacetaxine mepesuccinate.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Omacetaxine mepesuccinate.
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Omacetaxine mepesuccinate.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Omacetaxine mepesuccinate.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Omacetaxine mepesuccinate.
SeratrodastThe risk or severity of adverse effects can be increased when Seratrodast is combined with Omacetaxine mepesuccinate.
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Omacetaxine mepesuccinate.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Omacetaxine mepesuccinate.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Omacetaxine mepesuccinate.
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Omacetaxine mepesuccinate.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Omacetaxine mepesuccinate.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Omacetaxine mepesuccinate.
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Omacetaxine mepesuccinate.
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Omacetaxine mepesuccinate.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Omacetaxine mepesuccinate.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Omacetaxine mepesuccinate.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Omacetaxine mepesuccinate.
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Omacetaxine mepesuccinate.
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Omacetaxine mepesuccinate.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Omacetaxine mepesuccinate.
WarfarinThe risk or severity of adverse effects can be increased when Warfarin is combined with Omacetaxine mepesuccinate.
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Omacetaxine mepesuccinate.
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Omacetaxine mepesuccinate.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Omacetaxine mepesuccinate.
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Omacetaxine mepesuccinate.
Food Interactions
  • Homoharringtonine is administered subcutaneously, so food should have no effects.

Targets

Kind
Protein
Organism
Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809)
Pharmacological action
yes
Actions
antagonist
General Function:
Structural constituent of ribosome
Specific Function:
One of the primary rRNA binding proteins. Required for association of the 30S and 50S subunits to form the 70S ribosome, for tRNA binding and peptide bond formation. It has been suggested to have peptidyltransferase activity; this is somewhat controversial. Makes several contacts with the 16S rRNA in the 70S ribosome (By similarity).
Gene Name:
rpl2
Uniprot ID:
P20276
Molecular Weight:
25308.485 Da
References
  1. Gurel G, Blaha G, Moore PB, Steitz TA: U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol. 2009 May 29;389(1):146-56. doi: 10.1016/j.jmb.2009.04.005. Epub 2009 Apr 9. [PubMed:19362093 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Structural constituent of ribosome
Specific Function:
The L3 protein is a component of the large subunit of cytoplasmic ribosomes.
Gene Name:
RPL3
Uniprot ID:
P39023
Molecular Weight:
46108.72 Da
References
  1. Tujebajeva RM, Graifer DM, Matasova NB, Fedorova OS, Odintsov VB, Ajtkhozhina NA, Karpova GG: Selective inhibition of the polypeptide chain elongation in eukaryotic cells. Biochim Biophys Acta. 1992 Jan 6;1129(2):177-82. [PubMed:1730056 ]
  2. Tujebajeva RM, Graifer DM, Karpova GG, Ajtkhozhina NA: Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation. FEBS Lett. 1989 Nov 6;257(2):254-6. [PubMed:2583270 ]
Comments
comments powered by Disqus
Drug created on October 19, 2007 17:15 / Updated on September 30, 2016 02:27